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1983Lipoprotein(a) Levels in Familial HypercholesterolemiaAn Important Predictor of Cardiovascular Disease Independent
of the Type of LDL Receptor MutationObjectives TSeehe aim of this study was to determine the relationship between lipoprotein(a) [Lp(a)] and cardiovascular disease
(CVD) in a large cohort of patients with heterozygous familial hypercholesterolemia (FH).Background Lp(a) is considered a cardiovascular risk factor. Nevertheless, the role of Lp(a) as a predictor of CVD in patients
with FH has been a controversial issue.Methods A cross-sectional analysis of 1,960 patients with FH and 957 non-FH relatives recruited for SAFEHEART (Spanish
Familial Hypercholesterolemia Cohort Study), a long-term observational cohort study of a molecularly well-deﬁned
FH study group, was performed. Lp(a) concentrations were measured in plasma using an immunoturbidimetric
method.Results Patients with FH, especially those with CVD, had higher Lp(a) plasma levels compared with their unaffected
relatives (p< 0.001). A signiﬁcant difference in Lp(a) levels was observed when the most frequent null and defective
mutations in LDLR mutations were analyzed (p < 0.0016). On multivariate analysis, Lp(a) was an independent
predictor of cardiovascular disease. Patients carrying null mutations and Lp(a) levels >50 mg/dl showed the highest
cardiovascular risk compared with patients carrying the same mutations and Lp(a) levels <50 mg/dl.Conclusions Lp(a) is an independent predictor of CVD in men and women with FH. The risk of CVD is higher in those patients with
an Lp(a) level >50 mg/dl and carrying a receptor-negative mutation in the LDLR gene compared with other less
severe mutations. (J Am Coll Cardiol 2014;63:1982–9) ª 2014 by the American College of Cardiology FoundationHeterozygous familial hypercholesterolemia (FH) is a
frequent autosomal dominant inherited disorder associated
with premature cardiovascular disease (CVD). Its genetic bases
are rooted mainly in the low-density lipoprotein receptor
(LDLR) gene (1). It has been shown that at least 50% of male
subjects and 30% of female subjects with FH who do not
receive effective treatment will experience a coronary event by
50 years of age (2). Expression of CVD in affected subjects
varies considerably across cohorts and individual patients,
suggesting that other factors contribute to the atherosclerotic
burden in these patients (3–5).page 1990Lipoprotein(a) [Lp(a)] is a plasma lipoprotein consist-
ing of a low-density lipoprotein–like particle with one
additional protein, apolipoprotein(a), attached via a di-
sulﬁde bond to apolipoprotein B100 (6). Several epide-
miological and genetic studies have shown that high
Lp(a) levels can increase the risk of CVD in the general
population independent of low-density lipoprotein
cholesterol (LDL-C) levels and other cardiovascular risk
factors (6–8). However, the role of Lp(a) as a predictive
factor of CVD in patients with FH has been a long-term
controversial issue. Previous reports have shown either higher
levels of Lp(a) in subjects with FH who had coronary heart
disease or no differences when compared with subjects without
FH (5,9–12). Recently, some differences in Lp(a) levels
regarding the onset of CVD in male and female subjects with
FH have been reported (13).The aim of this study was to deﬁne the role of Lp(a) as a
predictor of CVD and the relationship with the type of LDLR
gene mutation in a large controlled cohort of patients with a
molecular diagnosis of heterozygous FH.
Methods
Study design and patients. The study design and patient
recruitment have been described previously (14). Brieﬂy,
SAFEHEART (Spanish Familial Hypercholesterolemia
Cohort Study) is an open, multicenter, long-term, obser-
vational, cohort study in a molecularly well-deﬁned popu-
lation of subjects with FH in Spain. A list of SAFEHEART
investigators appears in the Online Appendix. Six patients
with homozygous FH and 11 patients receiving nicotinic
acid were excluded from this analysis.
This study complies with the Declaration of Helsinki and
was approved by the local ethics committee. Written
informed consent was obtained from all participants before
their inclusion in the registry.
Measures and blood samples. Data collected on the de-
mographic and clinical characteristics of the subjects included
age, history of CVD, hypertension, type 2 diabetes mellitus,
smoking status, ﬁndings on physical examination, and current
lipid-lowering treatment. Information on a history of CVD
was obtained from medical charts provided by each subject’s
physician at inclusion in the study. Findings on physical ex-
amination included weight, height, body mass index (BMI),
and waist circumference. Blood pressure was measured twice
with each subject in a supine position using an Omron MX3
sphygmomanometer (Mannheim, Germany).
Abbreviations
and Acronyms
BMI = body mass index
CI = conﬁdence interval
CVD = cardiovascular
disease
FH = heterozygous familial
hypercholesterolemia
HDL-C = high-density
lipoprotein cholesterol
IQR = interquartile range
LDL-C = low-density
lipoprotein cholesterol
LDLR = low-density
lipoprotein receptor
Lp(a) = lipoprotein(a)
OR = odds ratio
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1984It was determined that CVD
was present if one of the following
criteria was documented: 1) myo-
cardial infarction proved by classic
criteria; 2) classic symptoms of
angina pectoris and one positive
result on an ischemic test or>70%
stenosis on coronary angiography;
3) percutaneous transluminal cor-
onary angiography (PTCA) or
coronary artery bypass grafting; 4)
ischemic stroke or documented
transitory ischemic attack; 5) in-
termittent claudication, which was
deﬁned as classic symptoms and
at least one positive result of an
ankle/arm index <0.9 or stenosis
>50% on angiography or ultraso-Table 1 Baseline Characteristics of Subjects (N ¼ 2,917)
Subjects
With FH
(n ¼ 1,960)
Subjects
Without FH
(n ¼ 957) p Value
Male 921 (47.0) 443 (46.3) 0.7520
Age, yrs 44.4  15.6 40.6  15.9 <0.0010
Current tobacco use 540 (27.6) 330 (34.5) <0.0010
BMI, kg/m2 26.5  5.2 26.0  5.1 <0.0100
CVD 247 (12.6) 41 (4.3) <0.0010
Premature CVD 193 (9.8) 25 (2.6) <0.0010
Age at ﬁrst event, yrs 48.3  12.3 53.7  10.2 <0.0030
Coronary artery disease 223 (11.4) 34 (3.6) <0.0010
Type 2 diabetes mellitus 77 (3.9) 38 (4.0) 0.9610
Arterial hypertension 284 (14.5) 121 (12.6) 0.1950
Tendinous xanthomas 266 (13.6) 0 (0) <0.0010
Total cholesterol, mg/dl 255  67.2 207  45.2 <0.0010
Triglycerides, mg/dl 83 (63–117) 85 (63–119.6) 0.6010
HDL-C, mg/dl 50  12.9 55  13.8 <0.0010
LDL-C, mg/dl 185  63.8 131  40.7 <0.0010
Lp(a), mg/dl 23.6 (9.6–59.2) 21.0 (7–47.2) <0.0001
Lp(a) >50 mg/dl 574 (29.3) 212 (22.2) <0.0001
Values are n (%), mean  SD, or median (interquartile range).
BMI ¼ body mass index; CVD ¼ cardiovascular disease; FH ¼ heterozygous familial hypercho-
lesterolemia; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein
cholesterol; Lp(a) ¼ lipoprotein(a).nography; 6) abdominal aortic aneurism; or 7) peripheral
arterial bypass grafting or percutaneous transluminal angio-
plasty. Premature CVD was deﬁned as the occurrence of the
ﬁrst event before 55 years of age in men and before 65 years of
age in women.
Venous blood samples were obtained after the subjects
fasted for 12 h. DNA was isolated from whole blood using
standard methods, and FH was diagnosed using a DNA
microarray (15). Plasma samples for measurement of Lp(a)
were stored at 20C and used within 3 weeks after they
were obtained according to the recommendation of the
manufacturer of the commercial assay. Serum total choles-
terol, triglyceride, and high-density lipoprotein cholesterol
(HDL-C) levels were measured using enzymatic methods.
LDL-C levels were calculated using the Friedewald formula.
Lp(a) levels were measured with a turbidimetric method
using immunoglobulin G anti-human Lp(a) (Quantia Lp(a)
7K00-01) in an Architect autoanalyzer C16000 (Abbott
Diagnostics, Lake Forest, Illinois) This assay is not inﬂuenced
by apolipoprotein(a) isoform size (16) and was calibrated
with the World Health Organization–approved, Inter-
national Federation of Clinical Chemistry and Laboratory
Medicine (IFCC) reference standard apolipoprotein(a)
with 21 kringle 4 repeats for standardization of Lp(a) (IFCC/
SRM 2B). Interassay variation for samples in the centralized
laboratory was <7%. Samples with hemolysis and/or lipemia
were excluded.
Mutations in the LDLR gene were classiﬁed as receptor-
negative (null) or receptor-defective (defective) depending
on their functional class as reported previously (17). Muta-
tions with an unknown biological effect were classiﬁed as
“unknown” but were considered functional if the autosomal
dominant trait was present in the family.
Statistical analysis. Statistical analyses were performed us-
ing the R programming language version 2.15.1 (2013,
Vienna, Austria). For quantitative variables with normal dis-
tribution, a descriptive analysis was performed using mean 
SD. For qualitative variables, the total number of cases andpercents were estimated. For quantitative variables lacking a
normal distribution, the median and the interquartile range
(IQR) were reported. Comparisons of frequencies between
qualitative variables were performed using the chi-square test.
Mean values of quantitative variables were compared with the
Student t test for independent data, and median values were
compared with the nonparametric Wilcoxon MannWhitney
rank sum test. The relationship between variables was
considered statistically signiﬁcant if the p value was <0.05.
Analysis of variance was conducted to identify interde-
pendency among variables, including age, sex, BMI, hyper-
tension, type 2 diabetes mellitus, xanthomas, smoking status,
Lp(a) levels, lipid levels, and type of mutation. Over inde-
pendent covariates, a Cox proportional hazards model was
performed to examine the relationship betweenCVD and one
or more variables. Signiﬁcant covariates were selected using
the Akaike information criterion method. A variable is
selected when the p value is <0.05. The magnitude of the
association was estimated using the odds ratio (OR) with a
conﬁdence interval (CI) of 95%.
A Kaplan-Meier estimate was performed to determine
the overall CVD-free survival time due to Lp(a) levels
(<50 mg/dl and >50 mg/dl) and the type of mutation (null
and defective) as well as sex (male and female). The failure
rate (the probability of a patient experiencing a CVD event
during a particular time under some conditions) was used to
plot the cumulative hazard. Comparison of Kaplan-Meier
estimators was performed using the log-rank test.
Results
A total of 2,917 subjects (1,960 patients with FH and 957
non-FH relatives) were included in this analysis. The clinical
Figure 1 Cumulative Hazard for CVD and Lp(a) levels
The solid line indicates patients with FH, and the dashed line indicates non-FH
subjects. CVD ¼ cardiovascular disease; FH ¼ heterozygous familial hypercho-
lesterolemia; Lp(a) ¼ lipoprotein(a).
Table 2 Lipid Proﬁle in the Study Group According to the Presence of CVD
(A)
FHþ CVDþ
(n ¼ 247)
(B)
FHþ CVD
(n ¼ 1,713)
(C)
FH CVDþ
(n ¼ 41)
(D)
FH CVD
(n ¼ 916)
Total cholesterol, mg/dl 225  54.8 260  67.7* 185  32.2y 208  45.5*y
Triglycerides, mg/dl 97 (70–129) 81 (62–129)* 98 (80–129) 84 (62–129)*z
HDL-C, mg/dl 46  11.4 51  11.4* 52  15.0z 55  15.0z
LDL-C, mg/dl 158  49.2 189  49.2* 109  24.4y 132  24.4*y
Non–HDL-C, mg/dl 179  52.9 209  67.8* 133  29.6y 153  44.2*y
Apo A1, mg/dl 133  25.0 140  27.6* 147  26.6z 151  58.0y
Apo B, mg/dl 111  30.0 122  37.9* 83  21.0y 91  26.3yx
Lp(a), mg/dl 43.4 (18.2–84.3) 21.3 (8.9–53.9)* 21.5 (8.4–37)z 20.8 (7–47.3)z
Lp(a) >50 mg/dl 114 (46.2) 460 (26.9)* 6 (14.6)y 206 (22.5)k
Values are mean  SD, median (interquartile range), or n (%). *p < 0.0001 and xp < 0.05 between A and B and between C and D; yp < 0.0001;
zp < 0.005, and kp < 0.05 between A and C and between B and D.
Abbreviations as in Table 1. Apo ¼ apolipoprotein.
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1985and biochemical characteristics of the subjects are shown in
Table 1. The mean age was 44.4 years for patients with
FH and 40.6 years for non-FH relatives (p < 0.001). In
total, 159 different functional mutations were identiﬁed in
the participants (data not shown). Almost 90% of patients
with FH were receiving stable lipid-lowering treatment at
inclusion in the study. In regard to the lipid proﬁle, patients
with FH had signiﬁcantly higher total cholesterol,
LDL-C, and Lp(a) levels and lower HDL-C levels (p <
0.001). In addition, the number of subjects with Lp(a) levels
>50 mg/dl was signiﬁcantly higher in the FH group
(p < 0.001). Male patients with FH had signiﬁcantly
higher Lp(a) levels compared with non-FH male subjects
(23.5 mg/dl [IQR: 9.5 to 57.2 mg/dl] vs. 19.5 mg/dl [IQR:
7.0 to 44.4 mg/dl]; p < 0.001), but there were no differences
between female subjects (23.5 vs. 21.5 mg/dl, respectively).
Lp(a) levels and CVD. Patients with FH and CVD had
signiﬁcantly higher Lp(a) levels than patients with FH
without CVD (p < 0.001) (Table 2). The percent of subjects
with Lp(a) levels >50 mg/dl was signiﬁcantly higher in
those with FH and CVD than in those without CVD
(p < 0.0001). Conversely, no differences in Lp(a) concen-
trations were noted in non-FH subjects according to CVD
status.
There were no signiﬁcant differences in Lp(a) levels (42.7
vs. 44.1 mg/dl, respectively) and in the number of subjects
withLp(a) levels>50mg/dl between the prematureCVDand
non- premature CVD groups (45.6% vs. 48.1%, respectively;
data not shown). Figure 1 shows the cumulative hazard curve
for CVD according to Lp(a) levels, showing that the risk was
signiﬁcantly higher for patients with FH compared with non-
FH subjects at any level beyond 50 mg/dl.
When analyzing Lp(a) levels and CVD according to
sex, female subjects with FH and CVD had signiﬁcantly
higher Lp(a) levels and there was a higher percent of
subjects with Lp(a) levels >50 mg/dl compared with male
subjects with FH and CVD (58.4 mg/dl [IQR: 22.0 to 97.2
mg/dl] vs. 35.4 mg/dl [IQR: 15.1 to 81.9 mg/dl] [p < 0.02]
and 56.4% vs. 41.1% [p < 0.03], respectively). Male subjects
with FH and CVD had signiﬁcantly higher levels of Lp(a)than non-FH male subjects with CVD (35.4 mg/dl [IQR:
15.1 to 81.9 mg/dl] vs. 21.5 mg/dl [IQR: 7.0 to 32.5
mg/dl]; p < 0.003) and there was a higher percent of sub-
jects with an Lp(a) level >50 mg/dl (41.1% vs. 12.5%;
p < 0.004). In female subjects, there were no differences in
Lp(a) levels between subjects with FH and CVD and non-
FH subjects with CVD. No differences were observed in
male and female subjects with FH regarding Lp(a) levels and
onset of CVD (data not shown). Figure 2 shows that CVD-
free survival time was signiﬁcantly reduced in male and
female subjects with FH and Lp(a) levels >50 mg/dl than
in subjects of the same sex and Lp(a) levels <50 mg/dl
(log-rank p value ¼ 0.0001).
Lp(a) levels and type of LDLR mutation. A nonsigniﬁ-
cant higher level of Lp(a) and percent of subjects with Lp(a)
levels >50 mg/dl was observed in patients carrying null mu-
tations compared with defective mutations (24.4 mg/dl
vs. 21.5 mg/dl and 30.2% vs. 28.1%, respectively). Because of
the high molecular heterogeneity, subjects carrying the most
Figure 2 Kaplan-Meier Curves for CVD-Free Survival in Subjects With FH According to Lp(a) Levels and Sex
The dashed gray line indicates male subjects with Lp(a) levels >50 mg/dl, the dashed black line indicates male subjects with Lp(a) levels <50 mg/dl, the gray solid line
indicates female subjects with Lp(a) levels >50 mg/dl, and the black solid line indicates female subjects with Lp(a) levels <50 mg/dl. Abbreviations as in Figure 1.
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1986frequent null and defective mutations (>50 cases per mutation)
were selected and analyzed. The 5 more common null muta-
tions were found in 500 subjects, whereas the 4 most commonFigure 3 Median Lp(a) Levels in Subjects With the Most Frequent N
Shaded bars indicate null mutations, and open bars indicate defective mutations. M1: c.
M5: c.1358þ1G>A; M6: c.2397_2405delCGTCTTCCTþc.1690A>C; M7: c.530C>T; M8:
as in Figure 1.defective mutations were found in 246 subjects. A signiﬁcant
difference in the median Lp(a) levels between null and
defective mutations was observed (p < 0.0016) (Fig. 3).ull Mutations and Defective Mutations Included in the Analysis
1342C>T; M2: c.97C>T; M3: c.313þ1G>Cþc274C>G; M4: c.460C>T;
c.2475C>A ; M9: c.1285G>A. IQR ¼ interquartile range; other abbreviations
Figure 4 Kaplan-Meier Curves for CVD-Free Survival in Subjects With FH According to Lp(a) Levels and Type of Mutation
The black solid line indicates null mutations and Lp(a) levels >50 mg/dl; the black dashed line indicates null mutations and Lp(a) levels <50 mg/dl; the gray solid line
indicates defective mutations and Lp(a) levels >50 mg/dl; and the gray dashed line indicates defective mutations and Lp(a) levels <50 mg/dl. Def ¼ defective; other
abbreviations as in Figure 1.
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1987Figure 4 shows that CVD-free survival time was signiﬁ-
cantly lower in patients carrying null mutations who had
Lp(a) levels >50 mg/dl (log-rank p value <0.0046)
compared with patients carrying defective mutations (log-
rank p value <0.0024). On the other hand, CVD-free
survival time in patients carrying null mutations and Lp(a)
levels <50 mg/dl and in those carrying defective mutations
and Lp(a) levels >50 mg/dl was similar.
Lp(a) levels were analyzed in non-FH subjects with high
cholesterol levels (total cholesterol level >250 mg/dl or
LDL-C level >190 mg/dl or receiving lipid-lowering
treatment) and CVD (n ¼ 36) and compared with those
of subjects with FH and CVD. Lp(a) levels wereTable 3
Cox Proportional Hazards Model Showing
Relationships Between Different Cardiovascular
Risk Factors and CVD in Patients With FH
Odds Ratio 95% Conﬁdence Interval p Value
Male 2.738 2.008–3.740 <0.0001
Current smoker 1.906 1.409–2.575 <0.0001
Xanthomas 1.488 1.089–2.032 <0.01
HDL-C <40 mg/dl 1.419 1.022–1.969 <0.03
BMI 1.035 1.006–1.066 <0.02
Lp(a) level 1.008 1.005–1.010 <0.0001
Triglyceride level 1.004 1.001–1.007 <0.02
Hypertension 1.287 0.964–1.719 0.08
Null mutation 1.282 0.962–1.710 0.09
Variables in the model included sex, tobacco use (current smokers), triglyceride levels, HDL-C
level <40 mg/dl, hypertension, type 2 diabetes mellitus, BMI, Lp(a) level, type of mutation (null
and defective), and xanthomas.
Abbreviations as in Table 1.signiﬁcantly lower in non-FH subjects with hypercholes-
terolemia compared with subjects with FH and CVD (21.5
mg/dl [IQR: 7.0 to 32.9 mg/dl] vs. 43.4 mg/dl [IQR: 18.2
to 84.3 mg/dl]; p < 0.0001; data not shown).
Multivariable analysis. The relationship of Lp(a) levels
with other CVD risk factors and the type of mutation as risk
predictors was assessed using the Cox proportional hazards
model (Table 3). The most important risk factors contrib-
uting to CVD in this FH study group were male sex (OR:
2.738; p < 0.0001), smoking (OR: 1.906; p < 0.0001);
xanthomas (OR: 1.488; p < 0.01); HDL-C level <40 mg/dl
(OR: 1.419; p < 0.03); BMI (OR: 1.035; p < 0.02), and
Lp(a) levels (OR: 1.008; p < 0.0001). In male subjects with
FH, Lp(a) continued to be an independent predictor of
CVD (OR: 1.007; 95% CI: 1.004 to 1.011; p < 0.0001) and
in female subjects with an Lp(a) level >50 mg/dl (OR:
2.387; 95% CI: 1.46 to 3.90; p < 0.0005).
Discussion
This study shows that patients with FH, especially
those with CVD, have signiﬁcantly higher Lp(a) levels
compared with their nonaffected relatives and that Lp(a) is
an independent predictor of CVD in this study group. This
effect seems to be independent of the type of mutation,
although patients with Lp(a) levels >50 mg/dl who are
carrying a null mutation have the highest risk of CVD.
Plasma Lp(a) levels are genetically determined, and it
seems that the major determinant of plasma levels is the
production, more than the clearance, of the lipoprotein (6).
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1988The role of the LDLR in Lp(a) uptake and degradation re-
mains unclear. Our ﬁndings are in agreement with some
previous studies showing higher Lp(a) levels in patients
with FH compared with healthy control patients and also
compared with non-FH relatives (18–21). The fact that non-
FH subjects with hypercholesterolemia have lower levels of
Lp(a) supports the role of LDLR in the catabolism of Lp(a).
Regarding the type of LDLR mutation, we observed a
nonsigniﬁcant trend toward higher Lp(a) levels in patients
carrying null mutations compared with those carrying
defective mutations. To decrease the variability, we restricted
the analyses to the most prevalent null and defective muta-
tions (38% of the cases). In this subset, we observed a sig-
niﬁcant difference in the median Lp(a) levels between both
groups of mutations, suggesting a role of LDLR in Lp(a)
plasma concentrations. Only one previous study has
analyzed the role of the type of LDLR mutation in Lp(a)
levels in FH. Leitersdorf et al. (22) showed in a small sample
of cases with 4 different mutations that, despite the fact that
the LDL-C levels were similar in all FH subgroups, the
Lp(a) levels were signiﬁcantly different among them. Also, it
has been shown that patients with homozygous FH have
higher Lp(a) levels than heterozygous subjects from the
same families, suggesting that LDLR mutations also result
in hyperlipoprotein(a) with a gene-dosage effect, although
the mechanism is not clear (23).
Elevated Lp(a) levels have been associated with an
increased risk of coronary, peripheral, and cerebrovascular
disease in the general population and in patients with FH
(10,18). Until now, the largest study analyzing Lp(a) levels
and CVD in the context of FH was the Dutch cohort that
showed a signiﬁcant association between Lp(a) levels >30
mg/dl and CVD (5). Another recent study has shown that
Lp(a) levels are different according to the onset of coronary
heart disease only in women with FH (13).
Our data show that Lp(a) is an independent predictor of
CVD in patients with FH. Patients with CVD had Lp(a)
concentrations that were twice as high as those in patients
with FH and non-FH relatives without CVD. Furthermore,
the increased risk is independent of age, sex, smoking status,
other lipoproteins, and the type of mutation in the LDLR
gene. On the other hand, no differences in Lp(a) levels
according to the onset of CVD were found.
According to the recent consensus in Lp(a) and CVD, we
used a cutoff of 50 mg/dl in Lp(a) levels to classify the risk
associated with this lipoprotein (6). To the best of our
knowledge, this is the ﬁrst study showing that subjects with
FH carrying the null mutation and Lp(a) levels >50 mg/dl
have the highest risk of CVD. Therefore, it may be advisable
to measure Lp(a) levels once in all patients with FH and, if
available, to perform DNA testing in LDLR to identify
those patients with a very high risk of CVD. Lp(a) levels are
resistant to most lifestyle interventions, and the efﬁcacy of
statins in reducing Lp(a) levels is still not well established
(6). To attain the recommended Lp(a) levels <50 mg/dl,
low-density lipoprotein apheresis may be useful in somepatients with severe FH because of the effectiveness in
removing Lp(a) (24). Moreover, emerging lipid-lowering
treatments can reduce Lp(a) levels up to 40% (25).
Study limitations. This is a large cross-sectional study of
patients with FH and their unaffected relatives. Therefore,
no conclusions about Lp(a) as a risk factor can be obtained.
Follow-up of the SAFEHEART population will provide
information about the role of Lp(a) and new cardiovascular
events and the relationship with other known cardiovascular
risk factors. The study design allowed for samples for Lp(a)
to be measured within 3 weeks in plasma stored at 20C,
thus avoiding problems of longer storage. Individual Lp(a)
levels are stable because they are strongly genetically deter-
mined (6). The size heterogeneity of apolipoprotein(a) due
to the presence of a multiple number of copies of kringle
4 type 2 affects the measurement of Lp(a) levels in plasma.
Previous controversy in the Lp(a) ﬁeld has been related to
the use of nonstandardized immunologically based assays,
differences in the composition and properties of antibodies
or calibrators, and sample storage, among others, making
comparison between different studies difﬁcult. Current
recommendations include the use of methods that are not
affected by the isoform size and the calibration with an in-
ternational standard (26). In this study, a validated assay
shown to be independent of the apolipoprotein(a) isoform
size used (16) and also was calibrated with the IFCC/SRM
2B standard, which will enable comparison of Lp(a) levels
with other studies and laboratories.
Conclusions
Lp(a) is an independent predictor of CVD in men and
women with FH, especially in those patients carrying
the most severe type of LDLR mutations. Therefore, our
results support the recent recommendations (6) that
Lp(a) levels should be measured in all patients with FH
as a marker that might help identifying high-risk subjects
who could beneﬁt from more aggressive lipid-lowering
treatments.
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APPENDIX
For a list of SAFEHEART investigators, please see the online version of this
article.Go to http://cme.jaccjournals.org
to take the CME quiz for this article.
